The present invention relates to a prodrug which comprises at least one pharmaceutically and/or diagnostically active compound bound by a cleavable linker, a receptor and/or antigen targeting moiety comprising a cyclic RGD peptide and a protein-binding moiety which is capable of binding to a carrier molecule.